Electric fields and pill combo takes on deadly brain tumor
NCT ID NCT04221503
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of the drug niraparib and a device that delivers electric fields (Tumor-Treating Fields) in 30 people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if the combo can control the tumor, shrink it, or keep it stable. Participants must have had prior radiation and have measurable disease on MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib (a PARP inhibitor) and Tumor-Treating Fields (electric fields delivered via a device)
What this could lead to
If it works, this could offer a new way to control recurrent glioblastoma, potentially slowing tumor growth and extending life.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States